TY - JOUR
T1 - Patient-reported outcomes and joint status across subgroups of US adults with hemophilia with varying characteristics
T2 - Results from the Pain, Functional Impairment, and Quality of Life (P-FiQ) study
AU - Batt, Katharine
AU - Boggio, Lisa
AU - Neff, Anne
AU - Buckner, Tyler W.
AU - Wang, Michael
AU - Quon, Doris
AU - Witkop, Michelle
AU - Recht, Michael
AU - Kessler, Craig
AU - Iyer, Neeraj N.
AU - Cooper, David L.
N1 - Funding Information:
K. Batt has received grant/research support from Novo Nordisk and is a scientific advisor for Precision Health Economics. L. Boggio is a consultant for Baxter, Bayer, Biogen, CSL Behring, Novo Nordisk, and Octapharma and has received research support from Baxter (Baxalta), Bayer, Biogen, CSL Behring, Novo Nordisk, Octapharma, OPKO, and Selexys. A. Neff has served on advisory boards for Baxalta, Kedrion, and Novo Nordisk. T. Buckner has served on advisory boards with CSL Behring, Genentech, Novo Nordisk, Pfizer, and Shire and as a consultant for Uniqure. M. Wang has served as a consultant to Baxalta, Biogen, CSL Behring, LFB, and Novo Nordisk. D. Quon is on advisory boards for Bayer, Bioverativ, Genentech, and Novo Nordisk and speakers bureaus for Bioverativ, Grifols, Novo Nordisk, Pfizer, and Shire. M. Witkop is currently Head of Research at the National Hemophilia Foundation. At the time of this research, she had received grant funding from Pfizer; served on advisory boards with Aptevo, Baxter Bioscience, Biogen Idec, Novo Nordisk, Octapharma, and Pfizer; and was on the Novo Nordisk Speakers Bureau. M. Recht has received grant/research support from Baxter, Biogen Idec, Novo Nordisk, and Pfizer and served as a consultant to Kedrion and Novo Nordisk. C. Kessler has served on advisory boards for Baxalta, Bayer, Biogen, Genentech, Grifols, Novo Nordisk, Octapharma, and Pfizer and has received grant/research support from Baxter, Bayer, Novo Nordisk, and Octapharma. N. Iyer is an employee of Novo Nordisk. D. Cooper is an employee of Novo Nordisk.
Publisher Copyright:
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
PY - 2018/4
Y1 - 2018/4
N2 - Introduction: Pain and functional impairment associated with joint disease are major problems for people with hemophilia, and impact on health-related quality of life (HRQoL) may vary across groups defined by demographic and treatment-related characteristics. Objective: To evaluate differences in overall HRQoL, pain, function, and joint status between P-FiQ study subgroups. Methods: Adult males with hemophilia and a history of joint pain/bleeding completed a pain history and the patient-reported outcome instruments EQ-5D-5L, Brief Pain Inventory v2 Short Form (BPI), International Physical Activity Questionnaire (IPAQ), and Hemophilia Activities List (HAL); optionally, joint status was assessed (Hemophilia Joint Health Score v2.1 [HJHS]). Scores were analyzed between subgroups across sets of participant characteristics. Results: A total of 381 adult males with hemophilia were enrolled, with median age of 34 years. Worse scores on EQ-5D-5L index, BPI pain severity/interference, HAL overall score, and HJHS were generally associated with being college educated, unemployment, self-reporting both acute and chronic pain, and self-reporting anxiety/depression. Conclusions: Measures of joint status and HRQoL were consistently lower in participants who had higher educational levels, were unemployed, self-reported having both acute and chronic pain, and self-reported having anxiety/depression. A greater understanding of the association of these factors with disease outcomes may improve individualized patient management.
AB - Introduction: Pain and functional impairment associated with joint disease are major problems for people with hemophilia, and impact on health-related quality of life (HRQoL) may vary across groups defined by demographic and treatment-related characteristics. Objective: To evaluate differences in overall HRQoL, pain, function, and joint status between P-FiQ study subgroups. Methods: Adult males with hemophilia and a history of joint pain/bleeding completed a pain history and the patient-reported outcome instruments EQ-5D-5L, Brief Pain Inventory v2 Short Form (BPI), International Physical Activity Questionnaire (IPAQ), and Hemophilia Activities List (HAL); optionally, joint status was assessed (Hemophilia Joint Health Score v2.1 [HJHS]). Scores were analyzed between subgroups across sets of participant characteristics. Results: A total of 381 adult males with hemophilia were enrolled, with median age of 34 years. Worse scores on EQ-5D-5L index, BPI pain severity/interference, HAL overall score, and HJHS were generally associated with being college educated, unemployment, self-reporting both acute and chronic pain, and self-reporting anxiety/depression. Conclusions: Measures of joint status and HRQoL were consistently lower in participants who had higher educational levels, were unemployed, self-reported having both acute and chronic pain, and self-reported having anxiety/depression. A greater understanding of the association of these factors with disease outcomes may improve individualized patient management.
KW - coagulation disorders
KW - quality of life
UR - http://www.scopus.com/inward/record.url?scp=85042711005&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042711005&partnerID=8YFLogxK
U2 - 10.1111/ejh.13028
DO - 10.1111/ejh.13028
M3 - Article
C2 - 29498783
AN - SCOPUS:85042711005
SN - 0902-4441
VL - 100
SP - 14
EP - 24
JO - European Journal of Haematology
JF - European Journal of Haematology
ER -